Overview

Stylus Medicine develops in vivo genetic medicines by combining engineered, therapeutic-grade recombinases with non-viral lipid nanoparticle (LNP) delivery. This platform enables sequence-specific genome integration to insert large genetic payloads directly inside a patient’s body, bypassing the complex steps of ex vivo cell modification. The initial focus is in oncology, delivering a recombinase and a CAR-encoding DNA payload to a patient’s T cells via LNP infusion, effectively turning the patient’s body into an in vivo CAR-T cell factory. The modular system can adapt CAR constructs to target different cancer antigens and holds potential for autoimmune and other genetic diseases beyond oncology. The company positions itself as an off-the-shelf, scalable genetic therapy approach that streamlines treatment workflows and broadens patient access by avoiding traditional ex vivo manufacturing.

Simplify's Take

What believers are saying

• Raised $85M in 2025 from RA Capital, Khosla, Lilly, and J&J.
• Preclinical in vivo CAR-T data presented at ASGCT 2025.
• Led by CEO Nuwaysir with 25+ years in cell therapy.

What critics are saying

• Prime Medicine's PRIME Editing partners with BMS in January 2025.
• Beam's base editing hits 40% efficiency in NHPs at ASGCT May 2025.
• Arc licenses Hsu's IP exclusively to CRISPR Therapeutics February 2026.

What makes Stylus Medicine unique

• Stylus combines engineered recombinases with LNP for in vivo genome integration.
• Platform enables precise insertion of multi-kb payloads into T-cells directly.
• Avoids ex vivo manufacturing complexities of traditional CAR-T therapies.

Help us improve and share your feedback! Did you find this helpful?

YesNo

Funding

Total Funding

$85M

Above

Industry Average

Funded Over

1 Rounds

$85,000,000

Series A

May 2025

Series A funding typically happens when a startup has a product and some customers, and now needs funding to scale. This money is usually used to grow the team, expand marketing, and improve the product. Venture capital firms are frequently the main investors here.

Series A Funding Comparison

Above Average

Industry standards

Ind Avg. $15M

$3.7M

$5M

$8.2M

$15M

$30M

$85M